Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

ASCO Issues Guidance on Second-Line Treatment of CRPC

April 25th 2017

Informed by new clinical evidence, ASCO has issued updated guidance on the use of second-line hormonal therapy for chemotherapy-naïve patients with castration-resistant prostate cancer.

Dr. Higano Discusses PARP Inhibitors in Prostate Cancer

April 25th 2017

Celestia Higano, MD, professor of medicine and urology at the University of Washington, and a member of the Clinical Research Division at Fred Hutchinson Cancer Research Center, discusses PARP inhibitors in prostate cancer.

Significance of Analyzing Gene Mutations in Prostate Cancer

April 25th 2017

Joshua Armenia, PhD, Memorial Sloan Kettering Cancer Center, discusses the significance of analyzing mutated genes in prostate cancer.

Expert Highlights Rapidly Evolving Biomarker Development in Prostate Cancer

April 24th 2017

Leonard Gomella, MD, discusses the future of biomarkers in prostate cancer.

Dr. Chapin on Impact of Active Surveillance in Field of Prostate Cancer

April 22nd 2017

Brian F. Chapin, MD, assistant professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses impact of active surveillance in the field of prostate cancer.

Dr. Slovin on the Future of Immunotherapy in Prostate Cancer

April 21st 2017

Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the future of immunotherapy for patients with prostate cancer.

Dr. Kane on Genetic Testing for Prostate Cancer

April 20th 2017

Christopher J. Kane, MD, professor of Surgery, chair, Department of Urology, UC San Diego Health, discusses the impact of genetic testing on patients with prostate cancer.

Dr. Crawford on Ongoing Trials of Genetic Testing for Prostate Cancer

April 20th 2017

E. David Crawford, MD, professor of Radiation Oncology, University of Colorado School of Medicine, discusses ongoing trials regarding genetic testing for patients with prostate cancer.

Next-Generation Therapies in CRPC Take Aim at AR Resistance

April 19th 2017

As a wealth of research has shown in the past several years, therapies that target the androgen receptor pathway in patients with castration-resistant prostate cancer encounter complex mechanisms of resistance including the likelihood that more than 1 such signaling network is active in each individual.

Dreicer Discusses Emerging Agents in mCRPC

April 15th 2017

Robert Dreicer, MD, highlights several emerging treatments for patients with metastatic castration-resistant prostate cancer.

Dr. Higano on Docetaxel for Hormone-Sensitive Prostate Cancer

April 14th 2017

Celestia Higano, MD, professor of Medicine and Urology, University of Washington, member of the Clinical Research Division at Fred Hutchinson Cancer Research Center, discusses results of docetaxel (Taxotere) versus hormone therapy in patients with metastatic hormone-sensitive prostate cancer.

AR-V7 Predicts Response in Castration-Resistant Prostate Cancer

April 12th 2017

The presence of androgen receptor splice variant-7 (AR-V7) mRNA in circulating tumor cells predicted poorer outcomes for men with castration-resistant prostate cancer assigned to novel hormonal therapies, according to results recently published in the Journal of Clinical Oncology.

Dr. Yu on Trials of Moderate Hypofractionation in Prostate Cancer

April 12th 2017

James B. Yu, MD, associate professor, therapeutic oncology, director, Prostate and Genitourinary Cancer Radiotherapy Program, Yale Cancer Center, discusses current data in support of using moderate hypofractionation in prostate cancer.

USPSTF Could Drop Its Opposition to Routine Prostate Cancer Screening

April 11th 2017

The US Preventive Services Task Force may move away from its long-standing opposition to routine PSA screening for prostate cancer in some men.

Dr. Slovin on Immunotherapy Agents for Prostate Cancer

April 11th 2017

Susan F. Slovin, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses potential immunotherapy agents for patients with prostate cancer.

New Checkpoint Inhibitor Approach Proposed in Prostate Cancer

April 7th 2017

Padmanee Sharma, MD, PhD, discusses the significance of the VISTA immune-checkpoint pathway in prostate cancer, and her proposed novel immunotherapy approach for patients with these tumors.

Prostate Cancer Advances Include Potential for PARP Inhibitors

April 6th 2017

Celestia Higano, MD, discusses the early use of chemotherapy, the potential for PARP inhibitors, and the evolving role of radium-223 in prostate cancer.

Dr. Dicker on the Impact of Genetic Testing for Prostate Cancer

April 5th 2017

Adam Dicker, MD, PhD, professor, chair, department of Radiation Oncology Sidney Kimmel Cancer Center, Thomas Jefferson University, discusses the impact of genetic testing for patients with prostate cancer.

Expert Discusses QoL Benefits of Active Surveillance for Low-Risk Prostate Cancer

March 29th 2017

Daniel A. Barocas, MD, discusses the benefits of active surveillance in patients with low-risk prostate cancer.

In Prostate Cancer, Moderate Hypofractionation Could Be New Standard

March 28th 2017

James B. Yu, MD, discusses results of a study on moderate hypofractionation in patients with prostate cancer, as well as recent data demonstrating how genomic testing can be helpful in postoperative treatment decision making.